# Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject

> **NCT02303509** · PHASE1 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 57 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** UCB5857 Part 1
- **DRUG:** UCB5857 Part 2
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02303509
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2014-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303509, "Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02303509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*